The Role of Some Hematological Parameters in Juvenile Systemic Lupue Erythematosus

Launched by ASSIUT UNIVERSITY · Jan 25, 2024

Keywords

ClinConnect Summary

This clinical trial is focused on understanding the role of certain blood characteristics in juvenile systemic lupus erythematosus (jSLE), which is a type of autoimmune disease where the body’s immune system mistakenly attacks its own tissues. This can lead to inflammation and damage in various organs, including the joints, kidneys, and the nervous system. The trial aims to gather more information about this condition to help improve diagnosis and treatment for young patients.

To participate in this study, candidates must be 18 years old or younger and diagnosed with jSLE based on specific medical guidelines. However, individuals with other autoimmune diseases, active infections, cancers, or certain blood and liver conditions will not be eligible. The trial is not yet recruiting participants, but once it begins, those involved will have the opportunity to contribute to important research that could enhance our understanding of jSLE and potentially improve care for future patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age at enrollment ≤18 years old.
• • 2. Both sexes
• • 3. The Patients should be diagnosed as jSLE, according to 2019 European league against rheumatism (EULAR)/ American college of rheumatology (ACR) SLE classification criteria, or the previous ACR 1997 SLE classification criteria.
• Exclusion criteria:
• • 1. Patients with autoimmune diseases other than j SLE
• • 2. Patients not fulfilling the criteria for diagnosis of SLE
• • 3. Active infections.
• • 4. Malignancies.
• • 5. Lymphoproliferative disorders.
• • 6. Hematologic diseases
• • 7. Hepatosplenic diseases and diabetic nephropathy